• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服万古霉素治疗抗生素相关性假膜性结肠炎后的症状性复发。

Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.

作者信息

Bartlett J G, Tedesco F J, Shull S, Lowe B, Chang T

出版信息

Gastroenterology. 1980 Mar;78(3):431-4.

PMID:7053190
Abstract

Twenty patients with antimicrobiol-associated diarrhea had a symptomatic relapse after oral vancomycin therapy. All patients had stool examinations which implicated C. difficile as the causative agent, and 16 had pseudomembranous colitis. Clinical courses were characterized by resolution of symptoms with recurrence of diarrhea at 4--21 days after vancomycin was discontinued. Studies of stools collected sequentially showed that vancomycin failed to eliminate C. difficile despite susceptibility to this agent with in vitro testing. A review of our records shows the incidence os symptomatic relapse is approximately 14%. This experience emphasizes the importance of adequate follow-up in patients treated with oral vancomycin for antibiotic-associated diarrhea or colitis due to C. difficile.

摘要

20例患有抗生素相关性腹泻的患者在口服万古霉素治疗后出现症状复发。所有患者均进行了粪便检查,结果表明艰难梭菌是病原体,其中16例患有假膜性结肠炎。临床病程的特点是在停用万古霉素后4 - 21天症状缓解,但腹泻复发。对连续收集的粪便进行研究表明,尽管体外试验显示艰难梭菌对万古霉素敏感,但万古霉素未能清除该菌。回顾我们的记录发现,症状复发的发生率约为14%。这一经验强调了对因艰难梭菌引起的抗生素相关性腹泻或结肠炎而接受口服万古霉素治疗的患者进行充分随访的重要性。

相似文献

1
Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.口服万古霉素治疗抗生素相关性假膜性结肠炎后的症状性复发。
Gastroenterology. 1980 Mar;78(3):431-4.
2
Treatment of recurrent antibiotic-associated pseudomembranous colitis.
Am J Gastroenterol. 1982 Apr;77(4):220-1.
3
[Relapsing infections with Clostridium difficile].[艰难梭菌复发性感染]
Ned Tijdschr Geneeskd. 2005 Oct 22;149(43):2381-5.
4
Bacitracin treatment of antibiotic-associated colitis and diarrhea caused by Clostridium difficile toxin.杆菌肽治疗艰难梭菌毒素引起的抗生素相关性结肠炎和腹泻。
Gastroenterology. 1980 Jun;78(6):1584-6.
5
Experimental studies of antibiotic associated colitis.抗生素相关性结肠炎的实验研究
Scand J Infect Dis Suppl. 1980(Suppl 22):11-5.
6
Pseudomembranous colitis: isolation of two species of cytotoxic clostridia and successful treatment with vancomycin.伪膜性结肠炎:两种细胞毒性梭状芽孢杆菌的分离及万古霉素治疗成功案例
Can Med Assoc J. 1978 Nov 4;119(9):1058-60.
7
Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.甲硝唑和万古霉素治疗艰难梭菌相关性疾病的临床及微生物学反应比较
Clin Infect Dis. 2008 Jul 1;47(1):56-62. doi: 10.1086/588293.
8
Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy.复发性假膜性结肠炎,与既往抗生素治疗无关。
Arch Intern Med. 1981 Apr;141(5):663-4.
9
Metronidazole: an alternate therapy for antibiotic-associated colitis.甲硝唑:抗生素相关性结肠炎的替代疗法。
Gastroenterology. 1982 May;82(5 Pt 1):849-51.
10
Relapse of pseudomembranous colitis after vancomycin therapy.
N Engl J Med. 1979 Aug 23;301(8):414-5. doi: 10.1056/NEJM197908233010806.

引用本文的文献

1
Fecal Microbiota Transplantation: Indications, Methods, and Challenges.粪便微生物群移植:适应症、方法及挑战
J Microbiol. 2024 Dec;62(12):1057-1074. doi: 10.1007/s12275-024-00184-3. Epub 2024 Nov 18.
2
2019 update of the WSES guidelines for management of () infection in surgical patients.2019 年 WSES 外科患者()感染管理指南更新。
World J Emerg Surg. 2019 Feb 28;14:8. doi: 10.1186/s13017-019-0228-3. eCollection 2019.
3
Structural Insights into Substrate Recognition by Sortase.分选酶对底物识别的结构见解
Front Cell Infect Microbiol. 2016 Nov 22;6:160. doi: 10.3389/fcimb.2016.00160. eCollection 2016.
4
Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.六种治疗复发性艰难梭菌感染策略的成本效益分析
PLoS One. 2016 Feb 22;11(2):e0149521. doi: 10.1371/journal.pone.0149521. eCollection 2016.
5
WSES guidelines for management of Clostridium difficile infection in surgical patients.WSES外科患者艰难梭菌感染管理指南。
World J Emerg Surg. 2015 Aug 20;10:38. doi: 10.1186/s13017-015-0033-6. eCollection 2015.
6
An agent-based simulation model for Clostridium difficile infection control.一种基于主体的艰难梭菌感染控制模拟模型。
Med Decis Making. 2015 Feb;35(2):211-29. doi: 10.1177/0272989X14545788. Epub 2014 Aug 11.
7
Variations in virulence and molecular biology among emerging strains of Clostridium difficile.艰难梭菌新菌株毒力和分子生物学的变异。
Microbiol Mol Biol Rev. 2013 Dec;77(4):567-81. doi: 10.1128/MMBR.00017-13.
8
MAPK-activated protein kinase 2 contributes to Clostridium difficile-associated inflammation.丝裂原活化蛋白激酶激活的蛋白激酶 2 有助于艰难梭菌相关性炎症。
Infect Immun. 2013 Mar;81(3):713-22. doi: 10.1128/IAI.00186-12. Epub 2012 Dec 21.
9
Clostridium difficile toxins: mechanism of action and role in disease.艰难梭菌毒素:作用机制及在疾病中的作用
Clin Microbiol Rev. 2005 Apr;18(2):247-63. doi: 10.1128/CMR.18.2.247-263.2005.
10
Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy.住院患者艰难梭菌相关性腹泻:社区和医院发病情况及乙状结肠镜检查的作用
Gut. 2004 May;53(5):673-7. doi: 10.1136/gut.2003.028803.